Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Research

Mazdutide (codes IBI362 / LY3305677) is a once-weekly GLP-1/glucagon dual agonist based on oxyntomodulin — a natural gut hormone that already hits both receptors. Originally discovered by Eli Lilly and licensed to Innovent Biologics, it's been developed mainly in China, where its phase 3 obesity data have been among the first for a GLP-1/glucagon agent in that market.

Research Background

Oxyntomodulin is a proglucagon-derived hormone that activates both the GLP-1 and glucagon receptors, but like other natural peptides it's too short-lived to use directly. Mazdutide is a synthetic oxyntomodulin analog with a fatty-acid side chain added for weekly dosing. Its development has run from phase 1b dose-ranging (2022) through phase 2 trials in both obesity and type 2 diabetes (2022–2024) to the pivotal phase 3 GLORY-2 obesity trial, all conducted in Chinese adults.

How It Works

The GLP-1 receptor arm drives glucose-dependent insulin secretion and central appetite suppression. The glucagon receptor arm adds increased energy expenditure and reduced hepatic fat. The historical challenge with GLP-1/glucagon coagonists is balance — glucagon can raise blood sugar and work against GLP-1's glucose-lowering — but mazdutide appears to tune that ratio so glycemic control holds while the metabolic and weight benefits come through.

What the Research Shows

• Obesity, phase 2 (Ji et al., *Nature Communications*, 2023): over 24 weeks, mean body-weight change was about -6.7%, -10.4%, and -11.3% across the 3, 4.5, and 6 mg doses, versus roughly +1% for placebo.
• Obesity, phase 3 GLORY-2 (*JAMA*, 2026): at the 9 mg dose over 60 weeks, mean weight change was about -16.7% versus -1.5% for placebo, and roughly 84% of participants lost at least 5% of body weight (versus about 33% on placebo).
• Type 2 diabetes, phase 2 (*Diabetes Care*, 2024): HbA1c fell by roughly 1.4 to 1.7 percentage points with mazdutide over 20 weeks, versus essentially no change on placebo, alongside meaningful weight loss.

Across trials the most common adverse events were gastrointestinal — nausea, vomiting, diarrhea, reduced appetite — mostly mild to moderate. Full citations are in the References section below.

Storage & Handling

Mazdutide is supplied in lyophilized (freeze-dried) form. Store it at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a sterile solvent, and avoid repeated freeze-thaw cycles.

Frequently Asked Questions

What is oxyntomodulin, and why does it matter here? Oxyntomodulin is a natural gut hormone that activates both the GLP-1 and glucagon receptors. Mazdutide is engineered from it, which is why it's a GLP-1/glucagon dual agonist rather than a GLP-1-only drug.

How is mazdutide different from survodutide? Both are GLP-1/glucagon dual agonists. Survodutide is a glucagon-based analog developed by Boehringer/Zealand; mazdutide is an oxyntomodulin-based analog developed by Innovent/Lilly and studied primarily in China.

What purity does Dynamite Research Peptides provide? Our mazdutide is 99%+ purity with a Certificate of Analysis for every batch.

All products are for research use only — not for human or animal consumption.